載入中
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
前收盤價
US$3.94
+US$0.30 · +8.24%
盤中時間採用ET。市場資料可能有所延遲。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日內區間
目前US$3.94
52週區間
目前US$3.94
盤中時間採用ET。市場資料可能有所延遲。
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
日內區間
目前US$3.94
52週區間
目前US$3.94
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1429萬 USD | 3657.1萬 USD | 3213萬 USD | 3173.7萬 USD | 2381.8萬 USD |
| 銷售、一般及管理費用 | 579.5萬 USD | 586.2萬 USD | 594.2萬 USD | 661.5萬 USD | 636.1萬 USD |
| 營業費用 | 2008.5萬 USD | 4243.3萬 USD | 3807.2萬 USD | 3835.2萬 USD | 3017.9萬 USD |
| 利息收入 | 12.6萬 USD | 33.8萬 USD | 23萬 USD | 5.2萬 USD | 3000 USD |
| 利息支出 | 732.9萬 USD | 554萬 USD | 279.2萬 USD | 103.3萬 USD | 48.9萬 USD |
| 折舊和攤銷 | 5.3萬 USD | 3.7萬 USD | 3.3萬 USD | 3.2萬 USD | 4.1萬 USD |
| 營業利益 | −2008.5萬 USD | −4243.3萬 USD | −3807.2萬 USD | −3835.2萬 USD | −3017.9萬 USD |
| 淨利 | −3083.6萬 USD | −4704.7萬 USD | −4106.6萬 USD | −3877.6萬 USD | −3052.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2012年3月23日 | 1:6 | — | — |
已生效 2012年3月23日
1:6
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI600.97萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM439.69萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF246.28萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO112.36萬0.01%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO108.81萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC54.71萬0.04%13.17億 USD0.60%US$183+0.11%
Horizon Kinetics Medical ETFMEDX16.73萬1.01%1658.37萬 USD0.85%US$35.2935+1.71%
Vanguard Russell 2000 Growth ETFVTWG14.16萬0.01%17億 USD0.06%US$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCHorizon Kinetics Medical ETFMEDXVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
